University of Melbourne collaboration with Telix receives Cancer Australia research grant
Melbourne (Australia) – 19th December 2019. Telix Pharmaceuticals announces University of Melbourne collaboration with Telix receives Cancer Australia research grant
Telix Pharmaceuticals Limited is pleased to announce that Telix collaborator Professor Frédéric Hollande from the University of Melbourne Centre for Cancer Research and colleagues have been successful in their Cancer Australia grant application entitled “The Preclinical Validation of Radio-labelled Girentuximab as a Theranostic Agent in Metastatic Colorectal Cancer”. The successful grant application was announced today by Cancer Australia.
To read the full media release please click here.